Please login to the form below

Not currently logged in
Email:
Password:

J&J sales up 8.3 per cent

Johnson & Johnson has reported total sales of $16.60bn for the second quarter of 2011, with strong international pharma growth countering a decline in US consumer products due in part to several recalls

Johnson & Johnson (J&J) has reported total sales of $16.60bn for the second quarter of 2011, an improvement of 8.3 per cent on 2010's performance.

Net profit for the company was down, however, decreasing from $3.45bn for Q2 2010 to $2.78bn for the same period in 2011. This year's figure was affected by an after-tax charge of $549m representing restructuring by Cordis Corporation, as well as litigation charges of $363m and a $54m cost for the recall of the DePuy ASRTM Hip.

The company's strongest area of growth was in pharmaceutical products sold outside the US. J&J made $2.99bn in the region, an increase of 22.6 per cent from 2010.

Behind this growth were recent product launches and approvals, including psoriasis treatment Stelara (ustekinumab); prostate cancer drug Zytiga (abiraterone acetate) and Invega Sustenna (paliperidone palmitate) for schizophrenia.

The strong international performance helped vounter a downturn in sales for the company's US consumer segment, with revenues down 8.5 per cent. J&J has faced several recalls and suspensions in the past year relating to products produced at its McNeil Consumer Healthcare facility in Fort Washington, Pennsylvania.

The company's half-year figures saw net earnings decrease too, with the company making $6.25bn for the first six months of 2011 compared to $7.98bn in 2010.

Sales for the period were up by 5.8 per cent, however, totalling $32.77bn.

19th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics